Diaverum shares publicly its recognised COVID-19 contingency plan to contribute to the combat against the pandemic

Diaverum, a leading global renal care service provider, shares its contingency plan with the worldwide nephrology community to contribute to the combat against COVID-19. 

The plan comprises the detailed policies and procedures successfully implemented to the group's dialysis clinics across the world to protect renal patients, healthcare professionals and manage the COVID-19 pandemic.

"We consider it our duty of care to share our knowledge and experience in managing the COVID-19 pandemic with the global nephrology community and the national healthcare systems. The battle against COVID-19 is a collective endeavour, and we hope that the hard work and knowledge of our global clinical teams will be beneficial for other clinicians and renal patients around the world", commented Dimitris Moulavasilis, CEO of Diaverum Group.

Haemodialysis patients are especially vulnerable to COVID-19 due to advanced average age, multiple comorbidities, a weakened immune system and some are particularly fragile. Besides, social circumstances also increase risk as they have to travel three times a week to receive dialysis treatment making adequate social isolation challenging. Health professionals are also at increased risk of contracting this disease. 

Diaverum operates in 22 countries and four continents with very different realities. Faced with this new situation, the group started to prepare early in January with the disease arriving in Europe. 

According to the Diaverum contingency plan, the clinics operate with new stringent protocols to minimise the risk of contagion, allow for quick identification of patients or staff with symptoms and ensure the right referral of each case. 

Strict measures are in place to keep patients at a safe distance from each other and avoid unnecessary interactions between patients or patients and staff. These measures include cancelling unnecessary activities, establishing different entry and exit patient routes, ensuring appropriate patient distance in waiting areas and revisiting patient transportation conditions.

Moreover, rigorous triage procedures were introduced to identify suspected patients before entering the clinic, while clinics were prepared to treat patients with COVID-19 in safe, isolated and controlled environments. 

The shared contingency plan includes all the policies and procedures implemented in the areas of patient transportation, triage implementation, waiting areas, treatment room, COVID-19 positive patients' treatment, human resources capacity, correct use of personal protective equipment, patient and staff education, supplies management, cleaning procedures.

It also includes a 76 points framework to ensure compliance.A copy of the plan can be downloaded here.

For more information, contact:

Michaela Blomstrand, Global Communications Manager, Diaverum Group

E-mail: michaela.blomstrand@diaverum.com

Phone: +46 766 43 30 26

About Diaverum

Diaverum provides life enhancing renal care to patients with Chronic Kidney Disease (CKD), enabling them to live fulfilling lives. Diaverum is a leading global provider in renal care services, and we help some 39,000 patients with 6 million treatments annually. Our vision is to transform renal care, to deliver the highest quality of care for patients and reduce total cost of care for payers. Our focus is haemodialysis, but we offer a portfolio of treatments ranging from preventive care, peritoneal dialysis and home care to coordination of patients’ comorbidities and transplantation services. Diaverum employs more than 11,000 employees and operates more than 400 clinics in 22 countries globally. Diaverum has its head office in Malmö, Sweden www.diaverum.com

About Us

Diaverum provides life enhancing renal care to patients with Chronic Kidney Disease (CKD), enabling them to live fulfilling lives. Diaverum is a leading global provider in renal care services and the largest independent provider in Europe, and we help some 39,000 patients with 6 million treatments annually. Our focus is haemodialysis, but we offer a portfolio of treatments ranging from preventive care, peritoneal dialysis and home care to coordination of patients’ comorbidities and transplantation services. CKD is a global and escalating challenge today affecting about 10% of the world’s adult population. It’s primarily caused by lifestyle diseases such as diabetes, and the prevalence is increasing in particular in developing countries. CKD disproportionately affects low income individuals and we ensure that our clinics are a safe and familiar space where all our patients are made to feel welcome. Diaverum’s vision is to transform renal care, to offer the highest quality of care and empower patients to live a fulfilling life. We work together with payers to reduce total cost of care while partnering with local communities to educate around health and the value of prevention. At the centre of what we do is our standardised, proprietary care delivery model, enabled by a continuously evolving digital infrastructure. We strive to ensure superior medical outcomes exceeding those demanded by national healthcare systems and we support patients by improving personalized care, ease of use and new services through technology. Diaverum employs more than 11,000 employees and operates more than 400 clinics in 22 countries globally. Diaverum has its head office in Malmö, Sweden.

Subscribe

Media

Media